Provectus Biopharmaceuticals Announces Abstract Available on PV-10 for Chemoablation of Liver Cancers at ESMO 17th World Cong...
June 24 2015 - 4:02PM
Business Wire
Provectus Biopharmaceuticals, Inc. (NYSE MKT:
PVCT,www.pvct.com), a clinical-stage oncology and dermatology
biopharmaceutical company ("Provectus" or the "Company"), announced
that the abstract titled, “Phase 1 Study of PV-10 for Chemoablation
of Hepatocellular Cancer and Cancer Metastatic to the Liver” to be
presented at the ESMO 17th World Congress on Gastrointestinal
Cancer is now available online at:
http://annonc.oxfordjournals.org/content/26/suppl_4/iv33.1.full?sid=82267ebd-da5c-4a1a-9320-a795571b6085
The abstract concludes “Preliminary efficacy in treatment of
liver tumors with PV-10 was observed. Toxicity was transient, and
treatment had acceptable tolerability. The study is continuing at
three study centers with two expansion cohorts to assess response
in hepatocellular carcinoma and other cancers metastatic to the
liver.”
Eric Wachter, PhD, Chief Technology Officer of Provectus, will
be the presenter, and is scheduled to make the presentation twice
during the Congress. Both presentations are scheduled for Thursday,
July 2, 2015; the first is from 10:30 to 11:00 a.m. and the second
from 4:55 to 5:25 p.m. local time.
Once the poster has been presented at the Congress, Provectus
will provide full details of its contents to the public.
About ESMO 17th World Congress on
Gastrointestinal Cancer
The ESMO 17th World Congress on Gastrointestinal Cancer is the
premier global event in the field, encompassing malignancies
affecting every component of the gastrointestinal tract and aspects
related to the care of patients with gastrointestinal cancer,
including screening, diagnosis and the latest management options
for common and uncommon tumours. It has been endorsed by leading
professional societies and organizations.
http://worldgicancer.com/WCGI/WGIC2015/index.asp
About Provectus Biopharmaceuticals, Inc.
Provectus Biopharmaceuticals, Inc. specializes in developing
oncology and dermatology therapies. PV-10, its novel
investigational drug for cancer, is designed for injection into
solid tumors (intralesional administration), thereby reducing
potential for systemic side effects. Its oncology focus is on
melanoma, breast cancer and cancers of the liver. The Company has
received orphan drug designations from the FDA for its melanoma and
hepatocellular carcinoma indications. PH-10, its topical
investigational drug for dermatology, is undergoing clinical
testing for psoriasis and atopic dermatitis. Provectus has
completed phase 2 trials of PV-10 as a therapy for metastatic
melanoma, and of PH-10 as a topical treatment for atopic dermatitis
and psoriasis. Information about these and the Company's other
clinical trials, including its current phase 3 study in melanoma,
can be found at the NIH registry, www.clinicaltrials.gov. For
additional information about Provectus, please visit the Company's
website at www.pvct.com or contact Porter, LeVay &
Rose, Inc.
FORWARD-LOOKING STATEMENTS: This release contains
"forward-looking statements" as defined under U.S. federal
securities laws. These statements reflect management's current
knowledge, assumptions, beliefs, estimates, and expectations and
express management's current views of future performance, results,
and trends and may be identified by their use of terms such as
"anticipate," "believe," "could," "estimate," "expect," "intend,"
"may," "plan," "predict," "project," "will," and other similar
terms. Forward-looking statements are subject to a number of risks
and uncertainties that could cause our actual results to materially
differ from those described in the forward-looking statements.
Readers should not place undue reliance on forward-looking
statements. Such statements are made as of the date hereof, and we
undertake no obligation to update such statements after this
date.
Risks and uncertainties that could cause our actual results to
materially differ from those described in forward-looking
statements include those discussed in our filings with the
Securities and Exchange Commission (including those described in
Item 1A of our Annual Report on Form 10-K for the year ended
December 31, 2014) and the following:
- our determination, based on guidance
from the FDA, whether to proceed with or without a partner with the
fully enrolled phase 3 trial of PV-10 to treat locally advanced
cutaneous melanoma and the costs associated with such a trial if it
is necessary to complete (versus interim data alone);
- our determination whether to license
PV-10, our melanoma drug product candidate, and other solid tumors
such as cancers of the liver, if such licensure is appropriate
considering the timing and structure of such a license, or to
commercialize PV-10 on our own to treat melanoma and other solid
tumors such as cancers of the liver;
- our ability to license our dermatology
drug product candidate, PH-10, on the basis of our phase 2 atopic
dermatitis and psoriasis results, which are in the process of being
further developed in conjunction with mechanism of action studies;
and
- our ability to raise additional capital
if we determine to commercialize PV-10 and/or PH-10 on our own,
although our expectation is to be acquired by a prospective
pharmaceutical or biotech concern prior to commercialization.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20150624006356/en/
Provectus Biopharmaceuticals, Inc.Peter R. Culpepper, CFO,
COO866-594-5999 #30orPorter, LeVay & Rose, Inc.Marlon Nurse,
DM, SVP – Investor Relations212-564-4700orTodd Aydelotte – Media
Relations646-428-0644
Provectus Biopharmaceuti... (QB) (USOTC:PVCT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Provectus Biopharmaceuti... (QB) (USOTC:PVCT)
Historical Stock Chart
From Apr 2023 to Apr 2024